• Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.


A potential treatment for patients with IgA nephropathy at risk of developing ESRD.


Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)

Share price Sweden

Share price US

Interim Report Q3 2020

On November 12, 2020, at 07:00 CET, Calliditas Therapeutics published its interim report for the third quarter 2020.